Abstract: Objective：To study the clinical efficacy and safety of salvianolate combined with trimetazibine in the treatment for patients with coronary heart disease and angina pectoris，and provide the reference for the future clinical treatment of coronary heart disease and angina pectoris. Methods： The 80 patients with coronary heart disease and angina pectoris in our hospital during the period from Jan 2016 to Jan 2017 were randomized into the control group(routine treatment of nitroglycerin) and the observation group(salvianolate combined with trimetazibine)， 40 patients per group. The clinical efficacy of treatment，daily episodes，duration time，nitroglycerin dosage，life quality on pretherapy and post-treatment and the adverse reactions during the treatment period in two groups were compared.Results： Compared with the control group， the total effect rates of clinical symptom treatment and ECG treatment were significantly increased in the observation group， and the difference was statistically significant（P<0.05）. Compared with the control group，the daily episodes， duration time，nitroglycerin dosage were obviously reduced in the observation group， and the difference was statistically significant（P<0.05）. Compared with the control group，the score of life quality was significantly increased on post-treatment in the observation group， and the difference was statistically significant（P<0.05）. There were no severe adverse reactions during the treatment period in two groups. Conclusion： The treatment of salvianolate combined with trimetazibine for coronary heart disease and angina pectoris can significantly increase the clinical efficacy， improve the patients′ life quality with higher clinical safety.